WO2001019797A3 - HYDROXYALKANOYL AMINOLACTAMES ET STRUCTURES ASSOCIEES, INHIBITEURS DE LA PRODUCTION DE LA PROTEINE A$g(b) - Google Patents

HYDROXYALKANOYL AMINOLACTAMES ET STRUCTURES ASSOCIEES, INHIBITEURS DE LA PRODUCTION DE LA PROTEINE A$g(b) Download PDF

Info

Publication number
WO2001019797A3
WO2001019797A3 PCT/US2000/024967 US0024967W WO0119797A3 WO 2001019797 A3 WO2001019797 A3 WO 2001019797A3 US 0024967 W US0024967 W US 0024967W WO 0119797 A3 WO0119797 A3 WO 0119797A3
Authority
WO
WIPO (PCT)
Prior art keywords
aminolactams
hydroxyalkanoyl
inhibitors
protein production
related structures
Prior art date
Application number
PCT/US2000/024967
Other languages
English (en)
Other versions
WO2001019797A2 (fr
Inventor
Richard Eric Olson
Hong Liu
Lorin Andrew Thompson Iii
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Priority to BR0014269-7A priority Critical patent/BR0014269A/pt
Priority to IL14777400A priority patent/IL147774A0/xx
Priority to EP00963374A priority patent/EP1212306A2/fr
Priority to CA002377221A priority patent/CA2377221A1/fr
Priority to AU74797/00A priority patent/AU783914B2/en
Priority to JP2001523377A priority patent/JP2003509411A/ja
Priority to MXPA02001813A priority patent/MXPA02001813A/es
Publication of WO2001019797A2 publication Critical patent/WO2001019797A2/fr
Publication of WO2001019797A3 publication Critical patent/WO2001019797A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention porte sur de nouveaux lactames de formule (I), sur leurs préparations pharmaceutiques, et sur leurs procédés d'utilisation. Ces nouveaux composés inhibent le processus de la protéine précurseur de l'amyloïde et plus spécifiquement la production du peptide Aβ, empêchant par là la formation de dépôts neurologiques de protéines amyloïdes. L'invention porte plus particulièrement le traitement des troubles neurologiques liés à production de l'amyloïde β, tels que la maladie d'Alzheimer et le syndrome de Down.
PCT/US2000/024967 1999-09-13 2000-09-13 HYDROXYALKANOYL AMINOLACTAMES ET STRUCTURES ASSOCIEES, INHIBITEURS DE LA PRODUCTION DE LA PROTEINE A$g(b) WO2001019797A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BR0014269-7A BR0014269A (pt) 1999-09-13 2000-09-13 Compostos de lactamas, seus sais e pró-drogas farmaceuticamente aceitáveis, composição farmacêutica, método de tratamento de disfunções neurológicas associadas com a produção de "beta"-amilóide, método de inibição da atividade da "alfa"-secretase e usos dos compostos
IL14777400A IL147774A0 (en) 1999-09-13 2000-09-13 Hydroxyalkanoyl aminolactams and related structures as inhibitors of as protein production
EP00963374A EP1212306A2 (fr) 1999-09-13 2000-09-13 HYDROXYALKANOYL AMINOLACTAMES ET STRUCTURES ASSOCIEES, INHIBITEURS DE LA PRODUCTION DE LA PROTEINE A$g(b)
CA002377221A CA2377221A1 (fr) 1999-09-13 2000-09-13 Hydroxyalkanoyl aminolactames et structures associees, inhibiteurs de la production de la proteine a.beta.
AU74797/00A AU783914B2 (en) 1999-09-13 2000-09-13 Hydroxyalkanoyl aminolactams and related structures as inhibitors of a beta protein production
JP2001523377A JP2003509411A (ja) 1999-09-13 2000-09-13 Ａβタンパク質の産生阻害剤としてのヒドロキシアルカノイルアミノラクタムおよび関連構造体
MXPA02001813A MXPA02001813A (es) 1999-09-13 2000-09-13 Hidroxialcanoilaminolactamas y estructuras relacionas como inhibidores de la produccion de la proteina abeta.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15351199P 1999-09-13 1999-09-13
US60/153,511 1999-09-13
US22438800P 2000-08-09 2000-08-09
US60/224,388 2000-08-09

Publications (2)

Publication Number Publication Date
WO2001019797A2 WO2001019797A2 (fr) 2001-03-22
WO2001019797A3 true WO2001019797A3 (fr) 2002-04-11

Family

ID=26850619

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/024967 WO2001019797A2 (fr) 1999-09-13 2000-09-13 HYDROXYALKANOYL AMINOLACTAMES ET STRUCTURES ASSOCIEES, INHIBITEURS DE LA PRODUCTION DE LA PROTEINE A$g(b)

Country Status (9)

Country Link
EP (1) EP1212306A2 (fr)
JP (1) JP2003509411A (fr)
CN (1) CN1399634A (fr)
AU (1) AU783914B2 (fr)
BR (1) BR0014269A (fr)
CA (1) CA2377221A1 (fr)
IL (1) IL147774A0 (fr)
MX (1) MXPA02001813A (fr)
WO (1) WO2001019797A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9139520B2 (en) 2007-12-21 2015-09-22 Ligand Pharmaceuticals Incorporated Selective androgen receptor modulators (SARMs) and uses thereof

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960576B2 (en) 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
US7119085B2 (en) 2000-03-23 2006-10-10 Elan Pharmaceuticals, Inc. Methods to treat alzheimer's disease
MXPA02009729A (es) * 2000-04-03 2003-03-27 Bristol Myers Squibb Pharma Co Lactamas ciclicas como inhibidores de la produccion de la proteina a-beta.
AU2001257006A1 (en) 2000-04-11 2001-10-23 Du Pont Pharmaceuticals Company Substituted lactams as inhibitors of abeta protein production
US6878363B2 (en) 2000-05-17 2005-04-12 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
GB0012671D0 (en) * 2000-05-24 2000-07-19 Merck Sharp & Dohme Therapeutic agents
EP1666452A2 (fr) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Composés pour le traitement de la maladie d'Alzheimer
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US7399775B2 (en) * 2001-12-27 2008-07-15 Daiichi Pharmaceutical Co., Ltd. β-amyloid protein production/secretion inhibitor
WO2003094854A2 (fr) 2002-05-07 2003-11-20 Elan Pharmaceuticals, Inc. Succinoyl aminopyrazoles et composes associes
TW200502221A (en) * 2002-10-03 2005-01-16 Astrazeneca Ab Novel lactams and uses thereof
JP4220548B2 (ja) 2003-06-05 2009-02-04 エラン ファーマシューティカルズ，インコーポレイテッド アシル化されたアミノ酸・アミジルピラゾール、および関連化合物
JP2010518064A (ja) 2007-02-12 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション Ａｄおよび関連状態の治療のためのピペラジン誘導体
EP2146722A4 (fr) 2007-05-10 2011-08-03 Amr Technology Inc Tétrahydrobenzo-l,4-diazépines substituées par un aryle ou un hétéroaryle et utilisation desdites dans le blocage de la réassimilation de la norépinéphrine, de la dopamine et de la sérotonine
EP2291181B9 (fr) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Utilisation de la captodiamine pour le traitement des symptômes de la dépression
EP3613418A1 (fr) 2014-01-17 2020-02-26 Ligand Pharmaceuticals, Inc. Procédés et compositions de modulation des niveaux d'hormones

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022433A1 (fr) * 1996-11-22 1998-05-28 Elan Pharmaceuticals, Inc. AMIDES D'ACIDES AMINES N-(ARYL/HETEROARYL/ALKYLACETYL), COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET METHODES D'INHIBITION DE LA LIBERATION DU PEPTIDE β-AMYLOIDE ET/OU SA SYNTHESE A L'AIDE DE CES COMPOSES
WO1998028268A2 (fr) * 1996-12-23 1998-07-02 Elan Pharmaceuticals, Inc. CYCLOALKYLE, LACTAME ET COMPOSES ASSOCIES, COMPOSITIONS PHARMACEUTIQUES CONTENANT CES COMPOSES, ET PROCEDES D'INHIBITION DE LA LIBERATION DU PEPTIDE β-AMYLOIDE ET/OU DE SA SYNTHESE AU MOYEN DE TELS COMPOSES
WO1999032453A1 (fr) * 1997-12-22 1999-07-01 Elan Pharmaceuticals, Inc. ⊂-CAPROLACTAMES α-AMINO POLYCYCLIQUES ET COMPOSES CONNEXES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
WO1999066934A1 (fr) 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. COMPOSES D'ACIDES AMINES CYCLIQUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET METHODES D'INHIBITION DE LA LIBERATION DU PEPTIDE β-AMYLOIDE ET/OU DE SA SYNTHESE A L'AIDE DE CES COMPOSES
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
WO2000038618A2 (fr) 1998-12-24 2000-07-06 Du Pont Pharmaceuticals Company BENZODIAZEPINES SUCCINOYLAMINO UTILISEES COMME INHIBITEURS DE LA PRODUCTION DE PROTEINE A$g(b)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022433A1 (fr) * 1996-11-22 1998-05-28 Elan Pharmaceuticals, Inc. AMIDES D'ACIDES AMINES N-(ARYL/HETEROARYL/ALKYLACETYL), COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET METHODES D'INHIBITION DE LA LIBERATION DU PEPTIDE β-AMYLOIDE ET/OU SA SYNTHESE A L'AIDE DE CES COMPOSES
WO1998028268A2 (fr) * 1996-12-23 1998-07-02 Elan Pharmaceuticals, Inc. CYCLOALKYLE, LACTAME ET COMPOSES ASSOCIES, COMPOSITIONS PHARMACEUTIQUES CONTENANT CES COMPOSES, ET PROCEDES D'INHIBITION DE LA LIBERATION DU PEPTIDE β-AMYLOIDE ET/OU DE SA SYNTHESE AU MOYEN DE TELS COMPOSES
WO1999032453A1 (fr) * 1997-12-22 1999-07-01 Elan Pharmaceuticals, Inc. ⊂-CAPROLACTAMES α-AMINO POLYCYCLIQUES ET COMPOSES CONNEXES

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M ADAMCZESKI & AL: "Novel Sponge-Derived Amino Acids. 5. Structures, Stereochemistry, and Synthesis of Several New Heterocycles", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 111, no. 2, 1989, pages 647 - 654, XP002171012 *
P J MAURER & M J MILLER: "Total synthesis of a mycobactin;mycobactin S2", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY,US,AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, vol. 105, no. 2, 1983, pages 240 - 245, XP002107931, ISSN: 0002-7863 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9139520B2 (en) 2007-12-21 2015-09-22 Ligand Pharmaceuticals Incorporated Selective androgen receptor modulators (SARMs) and uses thereof

Also Published As

Publication number Publication date
CN1399634A (zh) 2003-02-26
BR0014269A (pt) 2002-07-02
EP1212306A2 (fr) 2002-06-12
AU7479700A (en) 2001-04-17
CA2377221A1 (fr) 2001-03-22
AU783914B2 (en) 2005-12-22
JP2003509411A (ja) 2003-03-11
IL147774A0 (en) 2002-08-14
WO2001019797A2 (fr) 2001-03-22
MXPA02001813A (es) 2004-03-19

Similar Documents

Publication Publication Date Title
WO2000038618A3 (fr) BENZODIAZEPINES SUCCINOYLAMINO UTILISEES COMME INHIBITEURS DE LA PRODUCTION DE PROTEINE A$g(b)
WO2001060826A3 (fr) CARBOCYCLES ET HETEROCYCLES SUCCINOYLAMINO UTILISES EN TANT QU'INHIBITEURS DE LA PRODUCTION DE LA PROTEINE A$g(b)
CA2379445A1 (fr) Lactames substitues par des succinates cycliques en tant qu'inhibiteurs de la production de la proteine .beta.
WO2001019797A3 (fr) HYDROXYALKANOYL AMINOLACTAMES ET STRUCTURES ASSOCIEES, INHIBITEURS DE LA PRODUCTION DE LA PROTEINE A$g(b)
TR200100377T2 (tr) Aß Protein üretimi inhibitörleri olarak sukinoilamino laktamlar.
CA2171882A1 (fr) Inhibiteurs de la production de proteines de .beta.-amyloide
TW200502221A (en) Novel lactams and uses thereof
WO2003027068A3 (fr) Amines substituees pour le traitement de la maladie d'alzheimer
WO2004022523A3 (fr) Derives de promedicaments a base de 1, 3-diamino-2-hydroxypropane
MXPA04003245A (es) Hidroxipropilaminas.
WO2006026204A3 (fr) Nouvelles gamma-lactames servant d'inhibiteurs de beta-secretase
MXPA04000338A (es) Diamindioles para tratamiento de enfermedad de alzheimer.
WO2002064781A3 (fr) Regulation de l'expression de la proteine precurseur amyloide par modification de l'expression ou de l'activite du transporteur abc
EA200601607A1 (ru) Сульфонамидные соединения для лечения нейродегенеративных расстройств
CA2534532A1 (fr) Composes pour le traitement de maladies neurodegeneratives
WO2002100818A3 (fr) Aminediols pour le traitement de la maladie d'alzheimer
MXPA03011466A (es) Macrociclos utiles en tratamiento de enfermedades de alzheimer.
WO2005095348A3 (fr) Composes pyrazole-amines utilises dans le traitement des troubles neurodegeneratifs
WO2005097114A3 (fr) Composes de thiazole sulfamide utiles pour le traitement des maladies neurodegeneratives
WO2007034326A3 (fr) Composes imidazoles pour le traitement de troubles neurologiques
TW200504036A (en) Novel lactams and uses thereof
MXPA04000337A (es) Amindioles para tratamiento de enfermedad de alzheimer.
WO2000033788A3 (fr) Composes heterocycliques azotes substitues et leur utilisation therapeutique
WO2002094768A3 (fr) Composes ethylamine hydroxyles aza
CA2534529A1 (fr) Composes d'oxazole destines au traitement de troubles neurodegenerescents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN CZ EE HU IL IN JP KR LT LV MX NO NZ PL RO SG SI SK TR UA VN ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 74797/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 147774

Country of ref document: IL

Ref document number: 2377221

Country of ref document: CA

Ref document number: 516747

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2000963374

Country of ref document: EP

Ref document number: IN/PCT/2002/00162/DE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/001813

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2001 523377

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 008127840

Country of ref document: CN

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA CN CZ EE HU IL IN JP KR LT LV MX NO NZ PL RO SG SI SK TR UA VN ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWP Wipo information: published in national office

Ref document number: 2000963374

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 74797/00

Country of ref document: AU